Vor Biopharma (VOR)
(Delayed Data from NSDQ)
$0.72 USD
+0.04 (6.16%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $0.71 -0.01 (-0.96%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.72 USD
+0.04 (6.16%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $0.71 -0.01 (-0.96%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum D VGM
Zacks News
Why You Shouldn't Bet Against Vor Biopharma (VOR) Stock
by Zacks Equity Research
Vor Biopharma (VOR) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study
by Zacks Equity Research
Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 172.06%
by Zacks Equity Research
The mean of analysts' price targets for Vor Biopharma Inc. (VOR) points to a 172.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Can Vor Biopharma Inc. (VOR) Climb 298% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 298.3% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in Vor Biopharma Inc. (VOR)? Wall Street Analysts Think 295%
by Zacks Equity Research
The consensus price target hints at a 295% upside potential for Vor Biopharma Inc. (VOR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Vor Biopharma (VOR) Have the Potential to Rally 186% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 186.2% in Vor Biopharma (VOR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.